N-{(1R,3R)-3-[(2R,6S)-10-hydroxy-6,11,11-trimethyl-1,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocine-3-carbonyl]-cyclopentyl}-benzenesulfonamide | 1195979-85-1

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 6,7-苯并吗啡烷
• 英文名称: N-{(1R,3R)-3-[(2R,6S)-10-hydroxy-6,11,11-trimethyl-1,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocine-3-carbonyl]-cyclopentyl}-benzenesulfonamide
• 英文别名: N-[(1R,3R)-3-[(1S,9R)-6-hydroxy-1,13,13-trimethyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-triene-10-carbonyl]cyclopentyl]benzenesulfonamide
• CAS: 1195979-85-1
• 化学式: C₂₇H₃₄N₂O₄S
• 分子量: 482.644
• InChiKey: RQWVKBRWYPLGMJ-HODYICPISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  34
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  95.1
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  [(1R,3R)-3-amino-cyclopentyl]-[(2R,6S)-10-hydroxy-6,11,11-trimethyl-1,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocin-3-yl]-methanone 、 苯磺酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以35%的产率得到N-{(1R,3R)-3-[(2R,6S)-10-hydroxy-6,11,11-trimethyl-1,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocine-3-carbonyl]-cyclopentyl}-benzenesulfonamide
  参考文献：
  名称：

  Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use

  摘要：

  本发明涉及由式（I）定义的化合物，其中A、B、X、m、n和o基团的定义如权利要求1中所述，具有有价值的药理活性。特别是这些化合物是11β-羟基类固醇脱氢酶（HSD）1的抑制剂，因此适用于治疗和预防可以受到该酶抑制影响的疾病，如代谢性疾病，特别是2型糖尿病、肥胖症和血脂异常。

  公开号：

  US20110269791A1

文献信息

• ALICYCLIC CARBOXYLIC ACID DERIVATIVES OF BENZOMORPHANS AND RELATED SCAFFOLDS, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2288596B1

  公开（公告）日：2016-11-30
• US8765780B2
  申请人：——

  公开号：US8765780B2

  公开（公告）日：2014-07-01
• US9073870B2
  申请人：——

  公开号：US9073870B2

  公开（公告）日：2015-07-07
• [EN] ALICYCLIC CARBOXYLIC ACID DERIVATIVES OF BENZOMORPHANS AND RELATED SCAFFOLDS, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE<br/>[FR] DÉRIVÉS D'ACIDE CARBOXYLIQUE ALICYCLIQUE DE BENZOMORPHANES ET ÉCHAFAUDAGES AFFÉRENTS, MÉDICAMENTS CONTENANT CES COMPOSÉS, ET UTILISATION DE CEUX-CI
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009138386A2

  公开（公告）日：2009-11-19

  The present invention relates to compounds defined by Formula (I), wherein the groups A, B, X, m, n and o are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 1 1 β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity and dyslipidemia.
• Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use
  申请人：Peters Stefan

  公开号：US20110269791A1

  公开（公告）日：2011-11-03

  The present invention relates to compounds defined by Formula (I), wherein the groups A, B, X, m, n and o are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity and dyslipidemia.

  本发明涉及由式（I）定义的化合物，其中A、B、X、m、n和o基团的定义如权利要求1中所述，具有有价值的药理活性。特别是这些化合物是11β-羟基类固醇脱氢酶（HSD）1的抑制剂，因此适用于治疗和预防可以受到该酶抑制影响的疾病，如代谢性疾病，特别是2型糖尿病、肥胖症和血脂异常。